Background Respiratory disease is the main cause of morbidity and mortality in cystic
fibrosis (CF), and many different therapies are used by people with CF in the management of …

Background Cystic fibrosis is a life‐limiting inherited condition which affects one in 2500
newborns in the UK and 70,000 children and adults worldwide. The condition is multifaceted …

Background Recurrent wheeze and breathlessness are common in people with cystic
fibrosis, and bronchodilators are commonly prescribed. Despite their wide‐scale and often …

Introduction: Cystic fibrosis airways disease is characterized by chronic inflammation and
infection resulting in bronchiectasis. Published guidelines recommend medications for use …

The evidence base for modulator therapies in cystic fibrosis (CF) has continued to expand,
and it is likely that up to 90% of people with CF could benefit. Worldwide there are however …

Background The reduction of lung inflammation is one of the goals of cystic fibrosis therapy.
Inhaled corticosteroids are often used in this respect to treat children and adults with cystic …

Background Nebuliser systems are used to deliver medications to control the symptoms and
the progression of lung disease in people with cystic fibrosis. Many types of nebuliser …

In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been
proven to be highly effective. Consequently, an increasing number of drugs and devices …

Dry powder inhalers in cystic fibrosis: same old drugs but d... : Current Opinion in Pulmonary
Medicine Dry powder inhalers in cystic fibrosis: same old drugs but different benefits …

In spite of the widespread use of bronchodilators, there are very few long-term studies of
their effects in CF patients. However, there are clearly clinical benefits in certain situations …